AHCC shows promise in clearing HPV

Patients in the placebo group received a placebo for 12 months. The study found that 14 of 22 patients (63.6%) in the treatment arm became HPV-negative

AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections Front. Oncol., 22 June 2022 | https://doi.org/10.3389/fonc.2022.881902

https://www.eurekalert.org/news-releases/956667#.YrUfbtgh65k.wordpress

#HPV #AHCC #HumanPapillomavirus

#HPV #AHCC #HumanPapillomavirus #lentinula #ifn #igg1 #nk #infection #mushroom #immune

human papillomavirus, HPV, AHCC, NEGATIVE, active hexose correlated compound, lentinula edodes mycelia, MUSHROOM, INFECTION, IMMUNE, ONCOLOGY, interferon alpha, interferon beta, IFN, interferon gamma, IFN, IgG1, T lymphocytes, natural killer cell levels, NK